Charles Schwab
OMED

Charles Schwab’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Charles Schwab’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-61,985
Closed -$144K – 3182
2018
Q2 		$144K Buy
61,985
+3,612
+6% +$10.5K ﹤0.01% 3090
2018
Q1 		$186K Buy
58,373
+3,276
+6% +$9.03K ﹤0.01% 3002
2017
Q4 		$226K Buy
55,097
+4,368
+9% +$19K ﹤0.01% 2958
2017
Q3 		$230K Buy
50,729
+4,717
+10% +$19.1K ﹤0.01% 2973
2017
Q2 		$154K Sell
46,012
-35,987
-44% -$149K ﹤0.01% 3064
2017
Q1 		$756K Buy
81,999
+4,617
+6% +$40.5K ﹤0.01% 2516
2016
Q4 		$597K Buy
77,382
+4,158
+6% +$38.2K ﹤0.01% 2596
2016
Q3 		$837K Buy
73,224
+30,403
+71% +$354K ﹤0.01% 2451
2016
Q2 		$528K Buy
42,821
+588
+1% +$7.13K ﹤0.01% 2568
2016
Q1 		$427K Buy
42,233
+714
+2% +$8.38K ﹤0.01% 2639
2015
Q4 		$936K Buy
41,519
+910
+2% +$18.6K ﹤0.01% 2418
2015
Q3 		$674K Buy
40,609
+2,465
+6% +$49.4K ﹤0.01% 2516
2015
Q2 		$859K Buy
38,144
+7,066
+23% +$174K ﹤0.01% 2488
2015
Q1 		$802K Buy
31,078
+1,508
+5% +$38.2K ﹤0.01% 2459
2014
Q4 		$644K Buy
29,570
+793
+3% +$16.2K ﹤0.01% 2536
2014
Q3 		$545K Buy
28,777
+6,012
+26% +$121K ﹤0.01% 2554
2014
Q2 		$531K Buy
22,765
+10,220
+81% +$252K ﹤0.01% 2601
2014
Q1 		$423K Buy
12,545
+300
+2% +$10.1K ﹤0.01% 2658
2013
Q4 		$362K Buy
12,245
+360
+3% +$6.59K ﹤0.01% 2711
2013
Q3 		$188K Buy
+11,885
New +$220K ﹤0.01% 2942

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Charles Schwab's OMED Position: Q3 2018 in Review

Charles Schwab sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 61,985 shares — an estimated $144K sold.

Charles Schwab first reported a position in OMED in Q3 2013 and held it in 20 quarters. The position peaked at $936K in Q4 2015. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • Charles Schwab reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Charles Schwab sold 61,985 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $144K.
  • Charles Schwab first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 20 quarters.
  • Charles Schwab's OncoMed Pharmaceuticals, Inc. position peaked at $936K in Q4 2015.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Charles Schwab's 13F filing for Q3 2018, filed 13 Nov 2018.